Gastroenterology and Digestive Endoscopic Unit, Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144 Rome, Italy.
Cancer Epidemiol. 2011 Feb;35(1):44-7. doi: 10.1016/j.canep.2010.09.002. Epub 2010 Oct 13.
The risk of colorectal cancer (CRC) after BC and the additional risk factor of tamoxifen exposure were investigated by several studies with conflicting results. We performed a case-control study aimed at investigating if a past history of breast cancer is a risk factor of developing adenomas or CRC and establishing whether tamoxifen exposure is an additional risk factor.
We enrolled 175 asymptomatic women with a past history of BC and invited them to undergo a screening colonoscopy. In the same period, we enrolled 201 healthy asymptomatic women (HG) with no family history of CRC which were referred to our Unit for a colonoscopy.
Mean age at colonoscopy was 56.9 years for BC patients vs. 56.3 years for HG (p=0.58). In 32/175 (18.3%) BC patients, 38 lesions and in 17/201 (8.4%) controls, 20 lesions (p=0.029) were diagnosed. BC patients had 5/32 CRC vs. no CRC in the HG. Multivariate analysis of age, family history of CRC, timing from BC diagnosis and first colonoscopy, tamoxifen treatment revealed that none of the variables were predictive of the presence or absence of adenomas or CRC in the BC group.
In the present study BC group had a significant higher prevalence of adenoma or CRC than controls. Tamoxifen exposure did not increase the risk of adenoma or CRC. Our data support the hypothesis that BC is a risk condition for adenomas or CRC. The risk is small but present and a screening colonoscopy should be offered to these patients.
几项研究调查了乳腺癌 (BC) 后结直肠癌 (CRC) 的风险以及他莫昔芬暴露的附加风险因素,但结果存在冲突。我们进行了一项病例对照研究,旨在调查既往乳腺癌史是否是发生腺瘤或 CRC 的危险因素,并确定他莫昔芬暴露是否是另一个危险因素。
我们招募了 175 名既往患有 BC 的无症状女性,并邀请她们进行筛查结肠镜检查。同期,我们招募了 201 名无 CRC 家族史的健康无症状女性 (HG),这些女性因其他原因被转诊至我们科室进行结肠镜检查。
BC 患者的结肠镜检查平均年龄为 56.9 岁,HG 为 56.3 岁 (p=0.58)。在 175 名 BC 患者中,有 32 名患者 (18.3%) 诊断出 38 处病变,在 201 名 HG 中,有 17 名患者 (8.4%) 诊断出 20 处病变 (p=0.029)。BC 患者中有 5 例/32 例 CRC,而 HG 中无 CRC。对年龄、CRC 家族史、BC 诊断与首次结肠镜检查之间的时间、他莫昔芬治疗等变量进行多变量分析后发现,BC 组中这些变量均不能预测腺瘤或 CRC 的发生。
在本研究中,BC 组的腺瘤或 CRC 患病率明显高于对照组。他莫昔芬暴露并未增加腺瘤或 CRC 的风险。我们的数据支持这样一种假设,即 BC 是腺瘤或 CRC 的危险因素。这种风险虽然较小,但确实存在,应向这些患者提供筛查性结肠镜检查。